Dr. Nan Bi 毕楠
Chief Physician
Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Precise radiation therapy for thoracic tumors, including lung and esophageal cancer. Uses TOMO, intensity-modulated radiation therapy, and stereotactic radiation therapy. Combines radiation with chemotherapy, immunotherapy, and targeted therapy.
Dr. Bi holds dual doctoral degrees in clinical medicine from Peking Union Medical College. From 2012 to 2013, Dr. Bi was a postdoctoral fellow in the Department of Radiation Oncology at the University of Michigan. Dr. Bi has published nearly 20 papers, contributed to one English and multiple Chinese monographs, and participated in several national-level major projects.
Professional roles
- Member, Radiation Therapy Group of the Lung Cancer Professional Committee, China Anti-Cancer Association
- Youth Member, Branch of Radiation Oncology, Beijing Medical Association
Name order: in Chinese the family name comes first (Bi Nan). Papers usually list the name as Nan Bi or Bi N.
Selected publications
197 papers on PubMed matched by name and affiliation; 50 as first or senior author since 2016. Most recent first- or senior-author papers:
- Int J Radiat Oncol Biol Phys, 2026 (senior author): Peripheral PD-1⁺CD8⁺ T-cell TCR Dynamics During Radiation Therapy Predict Survival in Unresectable Locally Advanced Non-Small Cell Lung Cancer. PubMed 42142102
- Signal Transduct Target Ther, 2026 (first author): Induction and concurrent aumolertinib with radiotherapy for EGFR-mutated stage III NSCLC: results of phase III ADVANCE trial and real-world validation. PubMed 42764281
- Clin Transl Oncol, 2026 (senior author): Interpretable deep learning model of circulating genomics for quantitative survival prediction in advanced non-small cell lung cancer. PubMed 41649698
- Respir Res, 2026 (senior author): Single-cell mitophagy signature-based artificial intelligence model enhances prediction of prognosis and immunotherapy response in non-small-cell lung cancer. PubMed 41851738
- Int J Radiat Oncol Biol Phys, 2026 (senior author): In Reply to Noguchi et al. PubMed 41644225
- Int J Radiat Oncol Biol Phys, 2026 (senior author): Risk-Based Local Radiation Therapy in Oligometastatic Non-small Cell Lung Cancer in the Era of Immunotherapy: A Multicentric Cohort Study. PubMed 40578452
- Signal Transduct Target Ther, 2026 (senior author): Correction: Circulating tumor DNA refines consolidation immunotherapy for limited-stage small cell lung cancer patients. PubMed 41554704
- Mil Med Res, 2026 (senior author): PRIME: an interpretable artificial intelligence model based on liquid biopsy improves prediction of progression risk in non-small cell lung cancer. PubMed 41491583
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion